| Document |
Document Title |
|
WO/2024/095992A1 |
The present invention addresses the problem of providing a novel means for suppressing renal hypofunction, the means being capable of fundamentally improving diseases associated with renal hypofunction, including chronic kidney disease (...
|
|
WO/2024/097163A1 |
Methods of treating paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, or idiopathic immune complex-mediated glomerulonephritis using MASP-3 serine protease inhibitors are provided. In some embodiments, the MASP-3 serine p...
|
|
WO/2024/097138A1 |
Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant or reduced protein expression, and therapeutic agents which can target the alternative splicing events in the genes can m...
|
|
WO/2024/097620A1 |
Compositions and methods comprising antibodies that bind to integrin α3β1 are provided.
|
|
WO/2024/097861A1 |
Provided herein are methods of ameliorating a disease or disorder associated with dysregulation of the alternative complement pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.
|
|
WO/2024/093944A1 |
The present invention relates to the field of pharmaceutical chemicals, and in particular, to a solid dispersion of a curcumin derivative C66, a method for preparing same, and use thereof. In the solid dispersion described by the present...
|
|
WO/2024/092040A1 |
Provided herein are compounds that stabilize immunoglobulin light chains, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for ...
|
|
WO/2024/088315A1 |
Provided here are methods of treating primary membranous nephropathy in a patient in need thereof, comprising administering to said patient a BTK inhibitor, e.g., (S) -7- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetra...
|
|
WO/2024/092037A1 |
Provided herein are compounds that stabilize immunoglobulin light chains, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for ...
|
|
WO/2024/091489A1 |
Provided are compounds of the Formula (I):; or pharmaceutically acceptable salts thereof, which can be useful for the inhibition of Drp 1 and in the treatment of a variety of Drp 1l mediated conditions or diseases.
|
|
WO/2024/092043A1 |
Provided herein are compounds that stabilize immunoglobulin light chains, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for ...
|
|
WO/2024/091882A1 |
This patent document discloses novel compounds and methods of preventing or treating diseases or conditions related to Keapl-Nrf2interaction activity by use of the novel compounds. As direct inhibitors of Keapl-Nrf2 interaction, the comp...
|
|
WO/2024/092159A1 |
The present invention provides methods, systems, articles of manufacture, and kits related to treatment of muscle invasive bladder cancer with gemcitabine.
|
|
WO/2024/088175A1 |
Disclosed in the present disclosure are a gRNA targeting VEGFA, a gene editing system, and the use thereof. The gRNA in the present disclosure comprises a guide sequence which has at least 80% sequence identity to any one of SEQ ID NOs: ...
|
|
WO/2024/088307A1 |
Disclosed are a novel peptidyl nitrile compound and a use thereof, and specifically disclosed are a compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound and/or th...
|
|
WO/2024/092240A1 |
The present disclosure relates to the use of an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof, and isolated antibodies, including antigen-binding fragments thereof, which bind human APRIL for the treatment...
|
|
WO/2024/088364A1 |
The present disclosure relates to a pharmaceutical composition containing an isoquinolinone compound, and to a preparation method therefor. Specifically, the present disclosure provides a pharmaceutical composition containing 9,10-dimeth...
|
|
WO/2024/090521A1 |
Provided is a pharmaceutical composition for treating and/or preventing renal cystic ciliopathy, the composition containing a retinoic acid receptor (RAR) agonist.
|
|
WO/2024/087834A1 |
The present invention relates to a composition comprising a growth hormone fusion protein and a use thereof. The composition comprises: the growth hormone fusion protein and at least one of a buffering agent and a protective agent; a use...
|
|
WO/2024/088293A1 |
The present disclosure relates to a composition comprising an anti-MASP2 antibody, and the pharmaceutical use. Specifically, the present disclosure relates to a pharmaceutical composition comprising an anti-MASP2 antibody or an antigen-b...
|
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
|
WO/2024/085166A1 |
The present invention addresses the problem of: providing an anti-CLDN4-anti-CD137 bispecific antibody to be used in combination with a PD-1 signal inhibitor for treatment of a cancer, or a pharmaceutical composition comprising said bisp...
|
|
WO/2024/082383A1 |
The present invention provides an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody and a use thereof. The monoclonal antibody comprises three heavy chain complementarity determining regions CDR-H1, CDR-H2 and CDR-H3 and th...
|
|
WO/2024/083176A1 |
Disclosed are the uses of amniotic fluid in the preparation of a drug for treating and/or preventing macrophage-mediated diseases, a drug for treating and/or preventing type M1 macrophage-mediated diseases, a drug for treating and/or pre...
|
|
WO/2024/086240A1 |
Disclosed herein are compositions for supporting bladder health and/or treating, ameliorating, preventing, or reducing overactive bladder or the symptoms associated therewith. The compositions disclosed herein comprise a beta-adrenergic ...
|
|
WO/2024/086756A1 |
A method of treating, ameliorating, or preventing a condition characterized by one or both of reduced renal function and renal fibrosis is described, which includes interfering with one or both of an expression and an activity of a cadhe...
|
|
WO/2024/080441A1 |
The present invention provides: a Paracoccus aminovorans BM109 strain (accession number KCTC 15059BP), which is excellent for removing trimethylamine (TMA) or trimethylamine N-oxide (TMAO); and a pharmaceutical composition for preventing...
|
|
WO/2024/079471A1 |
A prebiotic oligosaccharide composition for use in reducing the level of ammonia. The composition comprises oligosaccharide compounds, for example galactooligosaccharide compounds, which includes: (a) at least 8 wt% Gal-(β1-3)-Gal-(β1-...
|
|
WO/2024/080323A1 |
Provided is a novel use of a composition that contains a prescribed sulfur-containing compound, a salt thereof, or both. The present invention is a sirtuin activator or expression enhancer, a NAD+ increasing agent, or a senescent cell in...
|
|
WO/2024/079324A1 |
The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said ...
|
|
WO/2024/077987A1 |
The present invention relates to the field of medicine. Specifically, disclosed is a PRDX1 IgG neutralizing antibody, which is a monoclonal neutralizing antibody against a PRDX1 protein or a polyclonal neutralizing antibody against the P...
|
|
WO/2024/079524A1 |
Provided herein are compositions and methods for treating kidney disease, for example diabetic kidney disease, using compositions comprising SDC2+ stromal stem cells.
|
|
WO/2024/077488A1 |
Use of a polygonum capitatum granular preparation in the preparation of drugs for clearing heat and promoting diuresis, inducing diuresis for treating stranguria, treating urinary tract infection or stones, treating pyelonephritis, detox...
|
|
WO/2024/077489A1 |
The use of a Polygonum capitatum Buch-Ham ex D. Don extract in the preparation of Relinqing granules for clearing heat and removing dampness, inducing diuresis for treating strangurtia, treating urinary system infections or stones, treat...
|
|
WO/2024/079331A1 |
The invention relates to the field of drug delivery for inflammatory diseases, more specifically inflammatory kidney, eye, lung, and intestinal diseases, and kidney, eye, lung and intestinal diseases in general.
|
|
WO/2024/080777A1 |
The present invention provides a pharmaceutical composition advantageously useful for preventing or treating nephritis.
|
|
WO/2024/077490A1 |
A method for improving the quality of a Polygonum capitatum extract and quality of Relinqing granules, said method comprising the following steps: (1) adding ethanol to a dry product of the overground part of a Polygonum capitatum medici...
|
|
WO/2024/074116A1 |
The present invention relates to use of a compound represented by formula (I) or an ester thereof or a pharmaceutically acceptable salt thereof in the treatment of a disease accompanied by fibrosis.
|
|
WO/2024/074105A1 |
The present invention belongs to the field of biopharmaceuticals. Provided in the present invention are keratin YK93-4, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell contain...
|
|
WO/2024/074102A1 |
The present invention pertains to the field of biopharmaceuticals and provides a keratin YK93-6, a nucleic acid molecule encoding same, an expression vector comprising the nucleic acid molecule, a host cell that contains the expression v...
|
|
WO/2024/074107A1 |
The present invention belongs to the field of biopharmaceuticals. Provided are a keratin YK93-2, a nucleic acid molecule encoding the same, an expression vector comprising the nucleic acid molecule, a host cell comprising the expression ...
|
|
WO/2024/074111A1 |
The present invention pertains to the field of biopharmaceuticals and provides a keratin YK93-9, a nucleic acid molecule encoding same, an expression vector comprising the nucleic acid molecule, a host cell that contains the expression v...
|
|
WO/2024/074110A1 |
The present invention relates to the field of biological pharmacy, provides keratin YK93-5, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or...
|
|
WO/2024/075139A1 |
The present application relates to an improved process for the preparation of finerenone and intermediates thereof, which is represented by the following structural formula-I.
|
|
WO/2024/074104A1 |
The present invention belongs to the field of biopharmaceuticals. Provided in the present invention are keratin YK93-8, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell contain...
|
|
WO/2024/076177A1 |
The present invention relates to a pharmaceutical composition comprising enavogliflozin as an active ingredient for the prevention or treatment of diabetes and/or renal diseases in patients who have or are at risk of diabetes and/or rena...
|
|
WO/2024/069191A1 |
The present invention provides a method of treating a patient suffering from bladder pain syndrome, said method comprising administering a solution containing a clostridial neurotoxin into the bladder of the patient; increasing the volum...
|
|
WO/2024/067756A1 |
The present invention relates to a drug, a dosage scheme, an administration interval, and an administration mode for treating membranous nephropathy with a TACI-Fc fusion protein. Results show that the TACI-Fc fusion protein provided by ...
|
|
WO/2024/071039A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2024/068808A1 |
A composition comprises at least two ingredients selected from the group consisting of: Fish oil, L-arginine, Vitamin E, Vitamin C, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B1, Vitamin B2, Folic acid, Biotin, Vitamin B12, and is formu...
|
